On-Demand: State of the Union for Advanced Medicines
Regenerative medicines are evolving at breakneck speed—and every advance has far-reaching implications. To be effective in CGTx development, you also need to understand the current investment landscape, new and exciting technologies, and the latest progress in drug development, manufacturing, regulatory, and reimbursement.
Sponsored by Precision ADVANCE, this Endpoints webinar with convene leading advanced therapy experts to discuss how to be effective in CGTx development. This discussion will be moderated by Anshul Mangal (President, Project Farma & Precision ADVANCE), and include insights from Phil Cyr (EVP, Precision Value & Health), David Greenwald (VP of Business Development, Deerfield Management), Rajul Jain (Managing Director, Vida Ventures), Joseph La Barge (CEO, Apertura Gene Therapy), and Adrian Woolfson (Executive Chairman, President & Co-Founder, Replay Bio).
Precision for Medicine Accelerating Precision Oncology with Next Generation Screening to Support New Cancer Diagnostics
BETHESDA, MD — Nov. 3, 2022 — Precision for Medicine, the first biomarker-driven clinical research organization (CRO) supporting life sciences companies in the use of biomarkers essential to targeting patient treatments more precisely and effectively, announces the culmination of a groundbreaking Next Generation Sequencing (NGS) initiative which improved the accuracy and speed of identifying cancer mutations in solid tumors, allowing researchers and manufacturers to develop patient-specific diagnostics for improved clinical outcomes.
On-Demand: What’s Next for Cell and Gene Therapies in 2023 and Beyond
At this years Meeting on the Mesa’s conference, Anshul Mangal: President (Precision ADVANCE and Project Farma) sat down with leading industry experts to discuss the future of cell and gene therapies.
On-Demand: Overcoming Manufacturing Challenges for Advanced Medicines
Sponsored by Precision ADVANCE, this Endpoints webinar with convene leading advanced therapy experts to discuss manufacturing strategies for next-generation medicines. This discussion will be moderated by Adam Pfeiffer (VP of Strategy, Project Farma), and include insights from Charlie Harper (VP, Project Farma), Brian Stamper (VP of Cell Therapy Operations, Immunomic Therapeutics Inc.), Jim Watson (VP, Project Farma), Brian Riley (Chief Manufacturing Officer, Beam Therapeutics), and Chad Salisbury (SVP, Project Farma).
On-Demand: Gene Therapy Roundup—What to know now from the lab to the FDA
Gene therapy continues to evolve rapidly – from the science to the regulatory requirements. To give you a greater perspective on recent developments, this panel discussion brings together gene therapy experts across assay development, regulatory submissions, and clinical trial strategy who will share observations from the front lines on a multitude of gene therapy and rare disease projects.